ArticleFrontiers in aging neuroscience2022
Identifying Mild Alzheimer's Disease With First 30-Min
Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Design of bifunctional pyridinophane ligands as MnInorganic chemistry frontiers · 2026Article
- Leveraging machine learning with dynamic 18F-FDG PET/CT: integrating metabolic and flow features for lung cancer differential diagnosis.European journal of nuclear medicine and molecular imaging · 2025Article
- Small Molecule Heterocycles: Design and Synthesis of Novel Fluorescent Benzothiazoles for Early Detection of Alzheimer's disease.Journal of sulphur chemistry · 2025Article
- Integration of Neuroimaging and Molecular Biomarkers in the Diagnosis of Alzheimer's Disease and Frontotemporal Dementia: The Promise of fMRI.Current Alzheimer research · 2025Review
- Two decades of [American journal of nuclear medicine and molecular imaging · 2024Review
- Reduced GLP-1R availability in the caudate nucleus with Alzheimer's disease.Frontiers in aging neuroscience · 2024Article
- Friends and Foes in Alzheimer's Disease.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023Review
- Advances in diagnosing mild cognitive impairment and Alzheimer's disease usingFrontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Introduction: Methods: Results: The Kruskal-Wallis test suggested that AQI, SUVR, and DVR can all differentiate between the healthy and subjects with mild AD ( Conclusion: Amyloid quantification index combines early-phase kinetic information and a certain degree of β-amyloid deposition, and can provide a better differentiating performance using the data from the first 30-min dynamic scan. Moreover, it was shown that clinically indistinguishable AD cases regarding PiB retention potentially can be correctly identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.